Results 161 to 170 of about 2,689,787 (296)

The European Union and Moldova [PDF]

, 2004
-, Wrobel, Jacek
core  

Hip Morphology–Based Osteoarthritis Risk Prediction Models: Development and External Validation Using Individual Participant Data From the World COACH Consortium

Arthritis Care &Research, EarlyView.
Objective This study aims to develop hip morphology‐based radiographic hip osteoarthritis (RHOA) risk prediction models and investigates the added predictive value of hip morphology measurements and the generalizability to different populations. Methods We combined data from nine prospective cohort studies participating in the Worldwide Collaboration ...
Myrthe A. van den Berg, Fleur Boel, Michiel M. A. van Buuren, Noortje S. Riedstra, Jinchi Tang, Harbeer Ahedi, Nigel K. Arden, Sita M. A. Bierma‐Zeinstra, Cindy G. Boer, Flavia M. Cicuttini, Timothy F. Cootes, David T. Felson, Willem Paul Gielis, Joshua Heerey, Graeme Jones, Stefan Kluzek, Nancy E. Lane, Claudia Lindner, Joyce B. J. van Meurs, Andrea Mosler, Amanda E. Nelson, Michael C. Nevitt, Edwin H. Oei, Jos Runhaar, Harrie Weinans, Jesse H. Krijthe, Rintje Agricola   +26 more
wiley   +1 more source

Dietary assessment and dietary guidelines across 11 European Union countries: a review from the PLAN'EAT project. [PDF]

Front Nutr
Aureli V, Grant F, Aguilar-Martínez A, Brons A, Fardet A, Chang B, Vespa F, Kirschner J, Kopczynska E, Böröcz L, Jacobsen M, Ghukasyan S, Manios Y, Gwozdz W, Antal E, Rossi L.   +15 more
europepmc   +1 more source

Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

Arthritis Care &Research, EarlyView.
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Kristine (Pek Ling) Ng, Annie Law, B. M. D. B. Basnayake, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Shirley Chan, C. S. Lau, Vera Golder, Alberta Hoi, Shereen Oon, Eric Morand, Mandana Nikpour, for the Asia‐Pacific Lupus Collaboration   +39 more
wiley   +1 more source

Do government outlays crowd-out private consumption? Evidence from the European Union. [PDF]

PLoS One
Bölükbaşı ÖF, Çolak O.
europepmc   +1 more source

The European Union [PDF]

, 1996
openaire   +1 more source

Zimbabwe and the European Union [PDF]

, 1997

core  

The prospects for Romania and state of the conduct ISPA Program [PDF]

European Union countries recorded growth rates differ. Therefore, the European policy of regional development aimed at ensuring heterogeneously and achieve the objective of convergence at European level must take into account the steps taken by each ...
Duduiala-Popescu, Lorena
core   +1 more source

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

Challenges and opportunities in the regulatory landscape of genetically modified crops in the European Union. [PDF]

Front Bioeng Biotechnol
Garcia-Alonso M, Alcalde E, Criel I, Novillo C, Kostolaniova P, Podevin N.   +5 more
europepmc   +1 more source